Assyro AI

FDA Orange Book · active-ingredient family

Prasugrel hydrochloride

Prasugrel hydrochloride is approved as 1 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:EFFIENT · NDA 022307

1

Brand (NDA)

10

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
EFFIENTRLD×2COSETTENDA 022307ABJul 10, 2009

Generic (ANDA) products (10)

ProductApplicantApplicationTEApproved
PRASUGREL HYDROCHLORIDE×2UNICHEMANDA 213315ABAug 28, 2023
PRASUGREL×2LUPINANDA 205930Jan 09, 2023
PRASUGREL×2SENORES PHARMSANDA 205926Jul 07, 2020
PRASUGREL×2HEC PHARMANDA 206021ABJan 16, 2019
PRASUGREL×2AMNEAL PHARMSANDA 205913Jun 19, 2018
PRASUGREL×2ACCORD HLTHCAREANDA 205987ABFeb 02, 2018
PRASUGREL×2AUROBINDO PHARMAANDA 205888ABOct 16, 2017
PRASUGREL×2CHARTWELL RXANDA 205790Oct 16, 2017
PRASUGREL×2PANACEAANDA 205897ABOct 16, 2017
PRASUGREL×2MYLANANDA 205927ABJul 12, 2017

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Prasugrel hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.